Results of Phase II Clinical Studies with Ukrain

A. LOHNINGER, J. MUSIANOWYC, F. JUDMAIER, D. MANFREDA, P. SPÄNGLER, H. ALBRECHT, J. HOFFMANN, and D. MEJER*

Second Department of Obstetrics and Gynecology. Vienna Medical School. Spitalgasse 23.1090 Vienna. Austria;
44 rue Jeanne d'Arc, Paris. Frances;
Allgem. Öffentl. Krankenhaus des Landes Kärnten in Klagenfurt. and HERA, Löblichgasse 4. A1090 Vienna. Austria;
Lukas Clinic. Brachmattstrasse 19, Arlesheim. Switzerland; and
Clinic for After Cancer Treatment. Welpeloweg 4, 75S6 BJ Overdinkel. The Netherlands*

Ukrain, tris(2-((5bS-(5ba,6b,12ba)]-5b,6,7,12b,13,14-hexahydro-13-methyl[1,3]benzodioxolo[5,6-c]-1,3-dioxolo[4,5-i]phenanthri-dinium-6-o)-ethaneaminyl)phosphinesulfide-6HCl, is widely used in oncological therapy, especially in cases where other therapy modalities show little or no successes. It is a semisynthetic compound, deriving from alkaloids of Chelidonium majus L. and thiophosphoric acid.